UCB released topline results of a phase 3b H2H "BE BOLD" RCT of bimekizumab (anti-IL17) vs rizankizumab (anti-IL23) in 550 active adult #PsA pts - at wk 16 inhibition of IL-17A/F was superior to IL-23 using the ACR50 primary endpoint. https://t.co/aWnHYefS2C https://t.co/2Vft5fouFv
Links:
UCB announces a head-to-head study evaluating BIMZELX[®]▼(bimekizumab) versus S…
https://buff.ly/4eI4bdF
30-09-2024